ArticleInternational journal of nanomedicine2014
Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells.
Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- NR4A1 expression aberrations contribute to radiotherapy resistance in gastric cancer.Scientific reports · 2025Article
- Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy.Bioactive materials · 2023Review
- Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Application of nanomedicine in radiotherapy sensitization.Frontiers in oncology · 2023Review
- Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment.Stem cell research & therapy · 2022Review
- Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.Bioengineering & translational medicine · 2022Review
- MiRNA-4537 functions as a tumor suppressor in gastric cancer and increases the radiosensitivity of gastric cancer cells.Bioengineered · 2021Article
- miR-29b-3p Increases Radiosensitivity in Stemness Cancer CellsFrontiers in cell and developmental biology · 2021Article
- Nanoparticles in Gastrooncology.Visceral medicine · 2020Review
- Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells.Cell death & disease · 2019Article
- Targeting cancer stem cells in drug discovery: Current state and future perspectives.World journal of stem cells · 2019Review
- MicroRNA-200c-3p/ZEB2 loop plays a crucial role in the tumor progression of prostate carcinoma.Annals of translational medicine · 2019Article
- MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1.OncoTargets and therapy · 2019Article
- New physical approaches to treat cancer stem cells: a review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Reactive Oxygen Species-Mediated Tumor Microenvironment Transformation: The Mechanism of Radioresistant Gastric Cancer.Oxidative medicine and cellular longevity · 2018Review
- The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.Frontiers in molecular biosciences · 2017Review
- Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system.World journal of gastrointestinal oncology · 2016Review
- miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.Journal of molecular medicine (Berlin, Germany) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is the main locoregional control modality for many types of unresectable tumors, including gastric cancer. However, many patients fail radiotherapy due to intrinsic radioresistance of cancer cells, which has been found to be strongly associated with cancer stem cell (CSC)-like properties. In this study, we developed a nanoparticle formulation to deliver miR-200c, which is reported to inhibit CSC-like properties, and then evaluated its potential activity as a radiosensitizer. miR-200c nanoparticles significantly augmented radiosensitivity in three gastric cancer cell lines (sensitization enhancement ratio 1.13-1.25), but only slightly in GES-1 cells (1.06). In addition to radioenhancement, miR-200c nanoparticles reduced the expression of CD44, a putative CSC marker, and the percentage of CD44(+) BGC823 cells. Meanwhile, other CSC-like properties, including invasiveness and resistance to apoptosis, could be suppressed by miR-200c nanoparticles. CSC-associated radioresistance mechanisms, involving reactive oxygen species levels and DNA repair capacity, were also attenuated. We have demonstrated that miR-200c nanoparticles are an effective radiosensitizer in gastric cancer cells and induce little radiosensitization in normal cells, which suggests that they are as a promising candidate for further preclinical and clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.